TecanThere’s uncertainty and concern about whether AI will replace humans in workplaces. But Marco Ravot-Licheri, Head of Digital – Life Sciences Business at Tecan, told us that AI could increase laboratory productivity and make research more meaningful.
Scripta TherapeuticsBiotech’s biggest opportunity is not simply to generate more compounds faster, but to improve the biological hypotheses behind them and help focused companies turn shared datasets, better models and deep disease expertise into drugs more likely to work in patients.
Kurma PartnersEuropean biotech is seeing both encouraging momentum and challenges. Innovation from European academia continues to inspire therapeutic concepts.
Sofinnova PartnersThe recent resurgence of life sciences IPOs in the US highlights a persistent structural imbalance: Europe generates world-class science but struggles to finance and retain it. The European Life Sciences Coalition was created to address this gap by mobilizing institutional capital and strengthening the policy framework needed to scale European innovation at home.
Ethris GmbHThe COVID 19 pandemic demonstrated that Europe can move fast, take risk, and deliver world class vaccines when political will, science and capital are aligned. Treating vaccines as strategic assets, backed by sustained political and financial support, will be key to maintaining Europe’s long-term investment in public health and innovation.
Sofinnova PartnersCapital is tight and patience is being tested. Yet Europe’s life sciences sector continues to deliver. Innovation doesn’t stop when markets turn; it adapts and matures.
StifelAfter two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success.
Asebio - Miguel MéndezAt BioSpain 2025 European Biotechnology spoke with AseBio CEO Ion Arocena about Spain’s expansion in biotech and its role in a time of geopolitical tensions.
T. Rowe PriceIn addition to the uncertainty triggered by the US government with serious changes at the FDA and other healthcare institutions and an unclear stance of the US Secretary of Health and Human Services on various areas of innovation, the growing demand for health care services gives a positive momentum that can provide stability.
European Biosolutions CoalitionAs the global race for biosolutions intensifies, Europe is at a critical crossroads, and I am deeply concerned about the future of our continent’s biotech industry. While countries like China and the United States rapidly advance their biotech industries, Europe’s slow and not up-to-date regulatory system poses a significant risk to maintaining our leadership.